It’s been a turbulent few months for immuno-oncology and there’s been a lot of speculation about what that will mean in terms of sales and market share. Coming out of the fourth quarter earnings calls, there have been early signs of change and a lot of posturing about the impact of combination approvals expected later this year.
Taking stock, Bristol-Myers Squibb Co.’s Opdivo (nivolumab) is holding on, but Merck & Co. Inc
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?